CINC Stock Plunged: Here’s What Happened

The Situation

CinCor Pharma Inc (NASDAQ: CINC) shared -- a clinical-stage biopharmaceutical company that aims to advance clinical candidates with a focus on cardiovascular, metabolic, and kidney diseases -- plunged on Monday after the Phase 2 trial of its hypertension treatment didn’t meet primary endpoints. As of 12:00 PM, ET CINC shares dropped by 46.29%.

The Explanation

CinCor Pharma Inc went public on January 7, 2022, with an initial plan of raising $200 million. The company launched at $16 per share and reached its all-time high of $37.80 on Aug 26 before dropping to $14.25 as of press time.

The company said that its Phase 2 trial of baxdrostat, its hypertension treatment, didn’t meet its primary endpoint. However, the trial confirmed the safety profile and tolerability of the treatment.

See the $CINC chart performance here.

The Effect

CinCor Pharma Inc stock reported losses after it failed to meet the Phase 2 trial of its hypertension treatment expectations. The investors’ reaction happened despite the company remaining on track to meet with the US FDA in January to discuss its Phase 3 program plans.

Since investors can’t know for sure whether the company will successfully pass its Phase 3 program in January of 2023, it is more important to focus on CinCor’s business.

See full $LRN flow at: https://unusualwhales.com/stock/CINC/flow-overview

Unusual Whales does not confirm the information's truthfulness or accuracy of the associated references, data, and cannot verify any of the information. Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Options, investing, trading is risky, and losses are more expected than profits. Please do own research before investing. Please only subscribe after reading our full terms and understanding options and the market, and the inherent risks of trading. It is highly recommended not to trade on this, or any, information from Unusual Whales. Markets are risky, and you will likely lose some or all of your capital. Please check our terms for full details.
Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Certain investment planning tools available on Unusual Whales may provide general investment education based on your input. You are solely responsible for determining whether any investment, investment strategy, security or related transaction is appropriate for you based on your personal investment objectives, financial circumstances and risk tolerance. You should consult your legal or tax professional regarding your specific situation. See terms for more information.